Open Access
REVIEW
circRNAs in drug resistance of breast cancer
SEMA MISIR1,*, SERAP OZER YAMAN2, NINA PETROVIĆ3,4, CEREN SUMER5, CEYLAN HEPOKUR1, YUKSEL ALIYAZICIOGLU2
1 Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, 58010, Turkey
2 Department of Medical Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, 61000, Turkey
3 Laboratory for Radiobiology and Molecular genetics, “VINČA” Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of
Belgrade, Belgrade, 11000, Serbia
4 Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, 11000, Serbia
5 Comprehensive Cancer Center, Faculty of Life Science & Medicine, King’s College London, London, SE11UL, United Kingdom
* Corresponding Author: Sema Misir,
Oncology Research 2022, 30(4), 157-172. https://doi.org/10.32604/or.2022.027547
Received 03 November 2022; Accepted 28 December 2022; Issue published 31 January 2023
Abstract
Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of
cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for
BC treatment. One of the significant challenges during the treatment of BC represents resistance to
chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment.
Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a
large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends.
Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC
resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how
circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and
summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis
dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding
cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to
tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicininduced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may
give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the
identification of new therapeutic targets for the prevention of BC chemoresistance.
Keywords
Cite This Article
MISIR, S., YAMAN, S. O., PETROVIĆ, N., SUMER, C., HEPOKUR, C. et al. (2022). circRNAs in drug resistance of breast cancer.
Oncology Research, 30(4), 157–172. https://doi.org/10.32604/or.2022.027547